Back to search results

MRI Simulation for Radiation Therapy in Prostate, Liver, and Head and Neck Cancers

This study, called "Jump," is testing a new way to plan radiation therapy for people with prostate, recurrent adenocarcinoma, liver, or head and neck cancer. It uses an MRI Simulator (a special MRI scan) to help doctors precisely target tumors for radiation. The study aims to see if it's possible to use MRI simulation before planning radiation therapy (Phase I) and if adjusting radiation based on these MRI scans is effective (Phase II). You might be able to join if you are 18 or older, need radiation therapy for your cancer, and meet other health criteria. The main goals are to see if the MRI simulation is feasible and to track your quality of life for up to 24 months. The study status is currently unclear.

Study design
This is a Phase I/II interventional study with a planned enrollment of 86 participants. It is a feasibility study, meaning it's the first time this type of MR-guided planning is being examined at this institution.
What's involved
Participants will undergo an MRI Simulator scan to help plan their radiation therapy. In Phase I, radiation will follow standard practice, while in Phase II, radiation might be adjusted based on the MRI data.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured from baseline up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04545957

Jump: MR Simulation For Radiation Therapy Master Protocol

Recruiting
NAAges 18+InterventionalTreatment
Brigham and Women's Hospital
~86 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:MRI SimulatorRadiation Therapy

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of acquiring MRI simulation prior to radiation therapy planning
Measured over 1 Year
+1 more outcome measured

Conditions

Prostate Cancer
Recurrent Adenocarcinoma
Liver Cancer
Head and Neck Cancer

Explore related trials

Liver CarcinomaMalignant Head and Neck NeoplasmProstate Carcinoma

Where it's being run

2 sites across 1 states
Massachusetts2

Study leadership

  • Raymond Mak, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital

Who to contact

Raymond Mak, MD
[email protected]
617-632-5734
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have a confirmed malignancy requiring radiation therapy.
Age: 18 years or older
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
Ability to understand and the willingness to sign a written informed consent document.
Disease-specific eligibility criteria will be specified in the appropriate subprotocol.

Exclusion

For MRI involving contrast, history of allergic reactions attributed to gadolinium based IV contrast. Note: If patient will not receive contrast, this is not applicable
Participants who cannot undergo an MRI

What this trial measures

  • Feasibility of acquiring MRI simulation prior to radiation therapy planning1 Year

    Feasibility is defined as successfully enrolling patients, successfully acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data

  • Proportion of patients with QOL decline exceeding 2 x MIDbaseline up to 24 months

    12 points; MID of the EPIC-26 urinary irritative/obstructive domain is 6 points) measured by EPIC-26 urinary irritation/obstruction domain from baseline to 2 years